Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 3/20 | 0.42 |
| ▸ | PIM1 | P11309 | 1/20 | 0.41 |
| ▸ | NNMT | P40261 | 2/20 | 0.40 |
| ▸ | GRM2 | Q14416 | 5/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SYK | P43405 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | APP | P05067 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | TTR | P02766 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29502454 | 1.00 | TGFBR1 (0.42) | TGFBR1PIM1NNMTGRM2DPP4 | |
| SCHEMBL30752139 | 0.82 | KDM4E (0.39) | TGFBR1KDM4EL3MBTL1KMT2AALDH1A1 | |
| SCHEMBL17785204 | 0.82 | KDM4E (0.56) | KDM4EL3MBTL1KMT2ALMNAALDH1A1 | |
| SCHEMBL21241047 | 0.82 | KDM4E (0.39) | TGFBR1KDM4EL3MBTL1KMT2AALDH1A1 | |
| SCHEMBL22835129 | 0.80 | KDM4E (0.38) | TGFBR1DPP4DPP8KDM4EL3MBTL1 | |
| SCHEMBL16101197 | 0.79 | P2RX7 (0.59) | KDM4EKMT2AALDH1A1 | |
| SCHEMBL3999989 | 0.79 | NOS3 (0.46) | PIM1NNMTGRM2DPP4DPP8 | |
| SCHEMBL13824470 | 0.78 | PIM1 (0.42) | PIM1NNMTGRM2DPP4DPP8 | |
| SCHEMBL2828385 | 0.78 | PIM1 (0.50) | PIM1NNMTGRM2DPP4DPP8 | |
| SCHEMBL14982165 | 0.77 | MAPT (0.45) | KDM4EL3MBTL1KMT2ALMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1858854-B1 | PYRIDINE-2-CARBOXAMIDE DERIVATIVES AS MGLUR5 ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2014-05-07 | — | — | EP | claimed |
| WO-2010100050-A1 | PYRIDINE-2-YL-CARBOXYLIC ACID AMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-09-10 | — | — | WO | claimed |
| US-20100227887-A1 | PYRIDINE-2-YL CARBOXYLIC ACID AMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-09-09 | — | — | US | claimed |
| EP-1844044-B1 | THIAZOLE-4-CARBOXAMIDE DERIVATIVES AS MGLUR5 ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2010-07-21 | — | — | EP | claimed |
| US-7678815-B2 | Thiazole-4-carboxyamide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-03-16 | — | — | US | claimed |
| US-20080269256-A1 | PYRIDINE-2-CARBOXYAMIDE DERIVATIVES | JAESCHKE GEORG | 2008-10-30 | — | — | US | claimed |
| EP-1858854-A1 | PYRIDINE-2-CARBOXAMIDE DERIVATIVES AS MGLUR5 ANTAGONISTS | F. Hoffmann-La Roche AG (CH) | 2007-11-28 | — | — | EP | claimed |
| EP-1844044-A1 | THIAZOLE-4-CARBOXAMIDE DERIVATIVES AS MGLUR5 ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-10-17 | — | — | EP | claimed |
| WO-2006094639-A1 | PYRIDINE-2-CARBOXAMIDE DERIVATIVES AS MGLUR5 ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-09-14 | — | — | WO | claimed |
| US-20060199960-A1 | e.g. 6-Methyl-3-(pyridin-3-ylamino)-pyridine-2-carboxylic acid (4-methyl-thiazol-2-yl)-amide; metabotropic glutamate receptor antagonists (mGluR); central nervous system disorders, antidepressant, anxiolytc agent; psychosis, epilepsy, schizophrenia, Alzheimer's disease, cognitive disorders | HOFFMANN-LA ROCHE INC. | 2006-09-07 | — | — | US | claimed |
| US-20060160857-A1 | Thiazole-4-carboxyamide derivatives | HOFFMANN-LA ROCHE INC. | 2006-07-20 | — | — | US | claimed |
| WO-2006074884-A1 | THIAZOLE-4-CARBOXAMIDE DERIVATIVES AS MGLUR5 ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-07-20 | — | — | WO | claimed |
| US-20260042749-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2026-02-12 | — | — | US | disclosed |
| US-12545659-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2026-02-10 | — | — | US | disclosed |
| US-20240059674-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-02-22 | — | — | US | disclosed |
| US-20230303526-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-09-28 | — | — | US | disclosed |
| WO-2006094639-A1 | PYRIDINE-2-CARBOXAMIDE DERIVATIVES AS MGLUR5 ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-09-14 | — | — | WO | disclosed |
| US-20060199960-A1 | e.g. 6-Methyl-3-(pyridin-3-ylamino)-pyridine-2-carboxylic acid (4-methyl-thiazol-2-yl)-amide; metabotropic glutamate receptor antagonists (mGluR); central nervous system disorders, antidepressant, anxiolytc agent; psychosis, epilepsy, schizophrenia, Alzheimer's disease, cognitive disorders | HOFFMANN-LA ROCHE INC. | 2006-09-07 | — | — | US | disclosed |
| US-20060160857-A1 | Thiazole-4-carboxyamide derivatives | HOFFMANN-LA ROCHE INC. | 2006-07-20 | — | — | US | disclosed |
| WO-2006074884-A1 | THIAZOLE-4-CARBOXAMIDE DERIVATIVES AS MGLUR5 ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100227887-A1 | PYRIDINE-2-YL CARBOXYLIC ACID AMIDES | GRM2, GRM1, GRM3 | TGFBR1 1513/4885PIM1 3732/4885NNMT 2017/4885 |
| US-12545659-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK4 | TGFBR1 230/4885PIM1 405/4885NNMT 213/4885 |
| US-20080269256-A1 | PYRIDINE-2-CARBOXYAMIDE DERIVATIVES | CNR2, CNR1, CHRNA2 | TGFBR1 3043/4885PIM1 3010/4885NNMT 629/4885 |
| US-20060160857-A1 | Thiazole-4-carboxyamide derivatives | GRM1, GRM2, GRIA4 | TGFBR1 584/4885PIM1 3908/4885NNMT 2234/4885 |
| US-20260042749-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK4 | TGFBR1 250/4885PIM1 985/4885NNMT 701/4885 |
| US-20240059674-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | TGFBR1 1014/4885PIM1 274/4885NNMT 1954/4885 |
| US-20230303526-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | TGFBR1 1014/4885PIM1 274/4885NNMT 1954/4885 |
| US-20060199960-A1 | e.g. 6-Methyl-3-(pyridin-3-ylamino)-pyridine-2-carboxylic acid (4-methyl-thiazol-2-yl)-amide; metabotropic glutamate receptor antagonists (mGluR); central nervous system disorders, antidepressant, anxiolytc agent; psychosis, epilepsy, schizophrenia, Alzheimer's disease, cognitive disorders | GRM3, GRM2, GRM1 | TGFBR1 598/4885PIM1 3774/4885NNMT 1136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.